Nephrotoxicity induced by vascular endothelial growth factor inhibitors
Vascular endothelial growth factor (VEGF) is a special mitogen for vascular endothelial cells, an essential endogenous angiogenic cytokine, and the principal controller of vascular growth that plays a fundamental role in therapeutic angiogenesis pathways. VEGF-targeted therapy is categorized into th...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Diabetic Nephropathy Prevention
2022-01-01
|
| Series: | Journal of Nephropharmacology |
| Subjects: | |
| Online Access: | https://jnephropharmacology.com/PDF/npj-10435 |
| _version_ | 1811191268117577728 |
|---|---|
| author | Shirinsadat Badri Lillian Siberian Rasool Soltani Azadeh Moghaddas Sara Ataei Mahnaz Momenzadeh |
| author_facet | Shirinsadat Badri Lillian Siberian Rasool Soltani Azadeh Moghaddas Sara Ataei Mahnaz Momenzadeh |
| author_sort | Shirinsadat Badri |
| collection | DOAJ |
| description | Vascular endothelial growth factor (VEGF) is a special mitogen for vascular endothelial cells, an essential endogenous angiogenic cytokine, and the principal controller of vascular growth that plays a fundamental role in therapeutic angiogenesis pathways. VEGF-targeted therapy is categorized into the group of angiogenesis inhibitors that inhibit the expression or the activity of VEGF. It comprises counteracting VEGF antibodies, VEGF receptors, VEGF-trap, and tyrosine kinase inhibitor (TKIs) with selectivity for VEGF receptors. The kidney is both a target and a source of VEGF. VEGF may be a vital mediator to restore some types of renal diseases (e.g., non-diabetic renal diseases) and harmful in some other diseases (e.g., diabetes and diabetes complications). Due to their ability to prevent angiogenesis, VEGF inhibitors have been found as a powerful tool to treat angiogenesis-dependent diseases, including cancer and diabetic retinopathy. VEGF preserves the renal structure and function in normal physiologic conditions. Therefore, all treatments that inhibit the VEGF pathway may lead to renal disorders, especially renovascular diseases such as hypertension, proteinuria, nephrotic syndrome, decreased glomerular filtration rate (GFR), and thrombotic microangiopathy (TMA). In the present study, we reviewed some related reports and associated mechanisms, especially for hypertension and proteinuria. |
| first_indexed | 2024-04-11T15:03:33Z |
| format | Article |
| id | doaj.art-2b45265a9a2e478a88f553460aa35e9c |
| institution | Directory Open Access Journal |
| issn | 2345-4202 |
| language | English |
| last_indexed | 2024-04-11T15:03:33Z |
| publishDate | 2022-01-01 |
| publisher | Society of Diabetic Nephropathy Prevention |
| record_format | Article |
| series | Journal of Nephropharmacology |
| spelling | doaj.art-2b45265a9a2e478a88f553460aa35e9c2022-12-22T04:16:53ZengSociety of Diabetic Nephropathy PreventionJournal of Nephropharmacology2345-42022022-01-01111e4e410.34172/npj.2022.04npj-10435Nephrotoxicity induced by vascular endothelial growth factor inhibitorsShirinsadat Badri0Lillian Siberian1Rasool Soltani2Azadeh Moghaddas3Sara Ataei4Mahnaz Momenzadeh5Department of Clinical Pharmacy and Pharmacy Practice; Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, IranIndependent Researcher and Author, Toronto, Ontario, CanadaDepartment of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, IranDepartment of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, IranVascular endothelial growth factor (VEGF) is a special mitogen for vascular endothelial cells, an essential endogenous angiogenic cytokine, and the principal controller of vascular growth that plays a fundamental role in therapeutic angiogenesis pathways. VEGF-targeted therapy is categorized into the group of angiogenesis inhibitors that inhibit the expression or the activity of VEGF. It comprises counteracting VEGF antibodies, VEGF receptors, VEGF-trap, and tyrosine kinase inhibitor (TKIs) with selectivity for VEGF receptors. The kidney is both a target and a source of VEGF. VEGF may be a vital mediator to restore some types of renal diseases (e.g., non-diabetic renal diseases) and harmful in some other diseases (e.g., diabetes and diabetes complications). Due to their ability to prevent angiogenesis, VEGF inhibitors have been found as a powerful tool to treat angiogenesis-dependent diseases, including cancer and diabetic retinopathy. VEGF preserves the renal structure and function in normal physiologic conditions. Therefore, all treatments that inhibit the VEGF pathway may lead to renal disorders, especially renovascular diseases such as hypertension, proteinuria, nephrotic syndrome, decreased glomerular filtration rate (GFR), and thrombotic microangiopathy (TMA). In the present study, we reviewed some related reports and associated mechanisms, especially for hypertension and proteinuria.https://jnephropharmacology.com/PDF/npj-10435thrombotic microangiopathyglomerular filtration ratevascular endothelial growth factor |
| spellingShingle | Shirinsadat Badri Lillian Siberian Rasool Soltani Azadeh Moghaddas Sara Ataei Mahnaz Momenzadeh Nephrotoxicity induced by vascular endothelial growth factor inhibitors Journal of Nephropharmacology thrombotic microangiopathy glomerular filtration rate vascular endothelial growth factor |
| title | Nephrotoxicity induced by vascular endothelial growth factor inhibitors |
| title_full | Nephrotoxicity induced by vascular endothelial growth factor inhibitors |
| title_fullStr | Nephrotoxicity induced by vascular endothelial growth factor inhibitors |
| title_full_unstemmed | Nephrotoxicity induced by vascular endothelial growth factor inhibitors |
| title_short | Nephrotoxicity induced by vascular endothelial growth factor inhibitors |
| title_sort | nephrotoxicity induced by vascular endothelial growth factor inhibitors |
| topic | thrombotic microangiopathy glomerular filtration rate vascular endothelial growth factor |
| url | https://jnephropharmacology.com/PDF/npj-10435 |
| work_keys_str_mv | AT shirinsadatbadri nephrotoxicityinducedbyvascularendothelialgrowthfactorinhibitors AT lilliansiberian nephrotoxicityinducedbyvascularendothelialgrowthfactorinhibitors AT rasoolsoltani nephrotoxicityinducedbyvascularendothelialgrowthfactorinhibitors AT azadehmoghaddas nephrotoxicityinducedbyvascularendothelialgrowthfactorinhibitors AT saraataei nephrotoxicityinducedbyvascularendothelialgrowthfactorinhibitors AT mahnazmomenzadeh nephrotoxicityinducedbyvascularendothelialgrowthfactorinhibitors |